Consensus document of the spanish association for the study of the liver on the treatment of Hepatitis B infection (2012);Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012)

Gastroenterologia y Hepatologia

Volumn 35, Issue 7, 2012, Pages 512-528

  Buti, María ^a   García Samaniego, Javier ^a   Prieto, Martín ^a   Rodríguez, Manuel ^b   Sánchez Tapias, José María ^a   Suárez, Emilio ^a   Esteban, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSENSUS; DISEASE CLASSIFICATION; ECHOGRAPHY; HEALTH CARE ORGANIZATION; HEPATITIS B; HUMAN; LIVER BIOPSY; SERODIAGNOSIS; SPAIN; TREATMENT INDICATION;

ANTIVIRAL AGENTS; CARRIER STATE; COINFECTION; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PROGNOSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84864327024     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2012.04.006     Document Type: Article

References (127)

1. Bruguera M., Bañares R., Córdoba J., Jardí R., González-Lahoz J., et al. Documento de Consenso de la AEEH sobre el tratamiento de las infecciones por los virus de las hepatitis B y C. Gastroenterol Hepatol 2006, 29:216-230.
2. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
4. Weinbaum C.M., Williams I., Mast E.E., Wang S.A., Finelli L., Wasley A., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1-20.
5. Salleras L., Domínguez A., Bruguera M., Plans P., Costa J., Cardeñosa N., et al. Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination. Vaccine 2007, 25:8726-8731.
6. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
7. Manno M., Camma C., Schepis F., Bassi F., Gelmini R., Giannini F., et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004, 127:756-763.
8. Liu J., Yang H.I., Lee M.H., Lu S.N., Jen C.L., Wang L.Y., et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010, 139:474-482.
9. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
10. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
11. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-352.
12. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57:84-90.
13. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
14. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
15. Tai D.I., Lin S.M., Sheen I.S., Chu C.M., Lin D.Y., Liaw Y.F. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009, 49:1859-1867.
16. Kumar M., Sarin S.K., Hissar S., Pande C., Sakhuja P., Sharma B.C., et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134:1376-1384.
17. Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.
18. Sonneveld M.J., Rijckborst V., Boucher C.A., Hansen B.E., Janssen H.L. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52:1251-1257.
19. Liaw Y.F. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011, 53:2121-2129.
20. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
21. Hadziyannis S.J. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011, 55:183-191.
22. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
23. Raimondi S., Maisonneuve P., Bruno S., Mondelli M.U. Is response to antiviral treatment influenced by hepatitis B virus genotype. J Hepatol 2010, 52:441-449.
24. Rotman Y., Brown T.A., Hoofnagle J.H. Evaluation of the patient with hepatitis B. Hepatology 2009, 49:S22-S27.
25. Martinez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
26. Marcellin P., Ziol M., Bedossa P., Douvin C., Poupon R., de Ledinghen V., et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009, 29:242-247.
27. Fraquelli M., Rigamonti C., Casazza G., Donato M.F., Ronchi G., Conte D., et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol 2011, 54:621-628.
28. Fung J., Lai C.L., Cheng C., Wu R., Wong D.K., Yuen M.F. Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. Am J Gastroenterol 2011, 106:492-496.
29. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
30. Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. E.A.S.L.
31. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
32. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312-323.
33. Lampertico P., Del Ninno E., Vigano M., Romeo R., Donato M.F., Sablon E., et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37:756-763.
34. Papatheodoridis G.V., Manesis E., Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306-313.
35. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., et al. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10:298-305.
36. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
37. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
38. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
39. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
40. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
41. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
42. Chan H.L., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745-754.
43. Leung N., Peng C.Y., Hann H.W., Sollano J., Lao-Tan J., Hsu C.W., et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72-79.
44. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
45. Gish R.G., Lok A.S., Chang T.T., de Man R.A., Gadano A., Sollano J., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437-1444.
46. Shouval D., Lai C.L., Chang T.T., Gadano A., Wu S.S., Halota W., et al. Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901. Hepatology 2008, 48:722A.
47. Tenney D.J., Pokornowski K.A., Rose R.E., Baldick C.J., Eggers B.J., Fang J., et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009, 50:S10.
48. Chang T.T., Liaw Y.F., Wu S.S., Schiff E., Han K.H., Lai C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010, 52:886-893.
49. Marcellin P., Buti M., Gane E.J., Krastev Z., Flisiak R., Germanidis G., et al. Five years of treatment with tenofovir (TDF) for chronic hepatitis B infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011, 54:1011A.
50. Marcellin P., Heathcote E.J., Corsa A., Liu Y., Miller M.D., Kitrinos K.M. No detectable resistance to tenofovir disoproxil fumarate(TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection. Hepatology 2011, 54:480A.
51. Buster E.H., Hansen B.E., Lau G.K., Piratvisuth T., Zeuzem S., Steyerberg E.W., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002-2009.
52. Liaw Y.F., Jia J.D., Chan H.L., Han K.H., Tanwandee T., Chuang W.L., et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011, 54:1591-1599.
53. Rijckborst V., Hansen B.E., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010, 52:454-461.
54. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135:459-467.
55. Marcellin P., Piratvisuth T., Brunetto M., Bonino F., Lau G.K.K., Farci P., et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a+- lamivudine: results of 5-year post-treatment follow up. J Hepatol 2009, 50:S336.
56. Lee H.W., Lee H.J., Hwang J.S., Sohn J.H., Jang J.Y., Han K.J., et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010, 51:415-421.
57. Lutgehetmann M., Volzt T., Quaas A., Zankel M., Fischer C., Dandri M., et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008, 13:57-66.
58. Fleischer R.D., Lok A.S. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009, 51:787-791.
59. Sheng J.F., Bai X.F., Wu S.H., Chen J.J., Sheng J.F., Xie Y., et al. A novel combination regimen of peginterferon alfa-2a and entecavir results in sustained post-treatment HBsAg clearance in HBeAg-positive chronic hepatitis B (CHB). Hepatology 2011, 54:1017A.
60. Sung J.J., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
61. Lok A.S., Trinh H.N., Carosi G., Akarca U.S., Gadano A., Habersetzer F., et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the BELOW study. Hepatology 2011, 54:471A.
62. Zoutendijk R., Reijnders J.G., Brown A., Zoulim F., Mutimer D., Deterding K., et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011, 54:443-451.
63. van Boemmel F., De Man R.A., Ferenci P., Reijnders J.G., Bronowicki J.P., Fulop B., et al. Long-term follow-up evaluation of the efficacy and safety of tenofovir disoproxil fumarate (TDF) in a European multicenter (nucleos(t)ide experienced) hepatitis B virus HBV-infected cohort. Hepatology 2009, 50:409A.
64. van Bommel F., de Man R.A., Wedemeyer H., Deterding K., Petersen J., Buggisch P., et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51:73-80.
65. Yao F.Y., Terrault N.A., Freise C., Maslow L., Bass N.M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001, 34:411-416.
66. Fontana R.J., Hann H.W., Perrillo R.P., Vierling J.M., Wright T., Rakela J., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002, 123:719-727.
67. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., Sarin S.K., Tanwandee T., Leung N., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011, 54:91-100.
68. Shim J.H., Lee H.C., Kim K.M., Lim Y.S., Chung Y.H., Lee Y.S., et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010, 52:176-182.
69. Liaw Y.F., Sheen I.S., Lee C.M., Akarca U.S., Papatheodoridis G.V., Suet-Hing Wong F., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
70. Lange C.M., Bojunga J., Hofmann W.P., Wunder K., Mihm U., Zeuzem S., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001-2006.
71. Marzano A., Gaia S., Ghisetti V., Carenzi S., Premoli A., Debernardi-Venon W., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005, 11:402-409.
72. Todo S., Demetris A.J., Van Thiel D., Teperman L., Fung J.J., Starzl T.E. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991, 13:619-626.
73. Steinmuller T., Seehofer D., Rayes N., Muller A.R., Settmacher U., Jonas S., et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35:1528-1535.
74. Buti M., Mas A., Prieto M., Casafont F., Gonzalez A., Miras M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003, 38:811-817.
75. Gane E.J., Angus P.W., Strasser S., Crawford D.H., Ring J., Jeffrey G.P., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132:931-937.
76. Cholongitas E., Goulis J., Akriviadis E., Papatheodoridis G.V. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011, 17:1176-1190.
77. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349-360.
78. Xi Z.F., Xia Q., Zhang J.J., Chen X.S., Han L.Z., Wang X., et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009, 10:321-327.
79. Jiménez-Pérez M., Sáez-Gómez A.B., Mongil Poce L., Lozano-Rey J.M., de la Cruz-Lombardo J., Rodrigo-López J.M. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010, 42:3167-3168.
80. Fung J., Cheung C., Chan S.C., Yuen M.F., Chok K.S., Sharr W., et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011, 141:1212-1219.
81. Naoumov N.V., Lopes A.R., Burra P., Caccamo L., Iemmolo R.M., de Man R.A., et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001, 34:888-894.
82. Wong S.N., Chu C.J., Wai C.T., Howell T., Moore C., Fontana R.J., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007, 13:374-381.
83. Buti M., Mas A., Prieto M., Casafont F., González A., Miras M., et al. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007, 84:650-654.
84. Angus P.W., Patterson S.J., Strasser S.I., McCaughan G.W., Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48:1460-1466.
85. Sánchez-Fueyo A., Rimola A., Grande L., Costa J., Mas A., Navasa M., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000, 31:496-501.
86. Bienzle U., Gunther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811-819.
87. Roche B., Feray C., Gigou M., Roque-Afonso A.M., Arulnaden J.L., Delvart V., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003, 38:86-95.
88. Hussain M., Soldevila-Pico C., Emre S., Luketic V., Lok A.S. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl 2007, 13:1137-1144.
89. Lenci I., Tisone G., Di Paolo D., Marcuccilli F., Tariciotti L., Ciotti M., et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011, 55:587-593.
90. Kellerman S.E., Hanson D.L., McNaghten A.D., Fleming P.L. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003, 188:571-577.
91. Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
92. Pérez-Olmeda M., Nuñez M., García-Samaniego J., Ríos P., González-Lahoz J., Soriano V. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. AIDS Res Hum Retroviruses 2003, 19:657-659.
93. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palu G., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-624.
94. Soriano V., Puoti M., Bonacini M., Brook G., Cargnel A., Rockstroh J., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005, 19:221-240.
95. Rapti I.N., Hadziyannis S.J. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol 2011, 5:323-339.
96. Wang H.S., Han S.H. Management of hepatitis B in special patient populations. Clin Liver Dis 2010, 14:505-520.
97. Rockstroh J.K., Bhagani S., Benhamou Y., Bruno R., Mauss S., Peters L., et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
98. McMahon M.A., Jilek B.L., Brennan T.P., Shen L., Zhou Y., Wind-Rotolo M., et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007, 356:2614-2621.
99. Peters M.G. Special populations with hepatitis B virus infection. Hepatology 2009, 49:S146-S155.
100. Thio C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49:S138-S145.
101. Chu C.J., Lee S.D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008, 23:512-520.
102. Liu C.J., Chuang W.L., Lee C.M., Yu M.L., Lu S.N., Wu S.S., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504.
103. Liu Y.L., Kao M.T., Huang C.C. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005, 23:3957-3960.
104. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology 2007;45:1331-2; author reply 32-3.
105. Farci P., Mandas A., Coiana A., Lai M.E., Desmet V., Van Eyken P., et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994, 330:88-94.
106. Farci P., Roskams T., Chessa L., Peddis G., Mazzoleni A.P., Scioscia R., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
107. Wedemeyer H., Yurdaydin C., Dalekos G.N., Erhardt A., Cakaloglu Y., Degertekin H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011, 364:322-331.
108. Kamar N., Milioto O., Alric L., El Kahwaji L., Cointault O., Lavayssiere L., et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008, 86:611-614.
109. Fabrizi F., Dixit V., Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 2006, 24:781-788.
110. Kumar M., Satapathy S., Monga R., Das K., Hissar S., Pande C., et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007, 45:97-101.
111. Petersen J. HBV treatment and pregnancy. J Hepatol 2011, 55:1171-1173.
112. Tse K.Y., Ho L.F., Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005, 43:771-775.
113. Ayres A., Yuen L., Manoharan S., Glass A., Nguyen R., Ng W., et al. Lamivudine in late pregnancy for prevention of HBV transmission: effectiveness and detection of antiviral resistance. J Hepatol 2011, 54:S295.
114. Nguyen G., Garcia R.T., Nguyen N., Trinh H., Keeffe E.B., Nguyen M.H. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009, 29:755-764.
115. Iorio R., Giannattasio A., Cirillo F., Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007, 45:943-949.
116. Han G.R., Cao M.K., Zhao W., Jiang H.X., Wang C.M., Bai S.F., et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011, 55:1215-1221.
117. Jonas M.M., Mizerski J., Badia I.B., Areias J.A., Schwarz K.B., Little N.R., et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002, 346:1706-1713.
118. Jonas M.M., Kelly D., Pollack H., Mizerski J., Sorbel J., Frederick D., et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008, 47:1863-1871.
119. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45:1056-1075.
120. Kusumoto S., Tanaka Y., Ueda R., Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011, 46:9-16.
121. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:619-633.
122. Pérez-Alvárez R., Díaz-Lagares C., García-Hernández F., López-Roses L., Brito-Zerón P., Pérez-de-Lis M., et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011, 90:359-371.
123. Jang J.W., Choi J.Y., Bae S.H., Yoon S.K., Chang U.I., Kim C.W., et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006, 43:233-240.
124. Katz L.H., Fraser A., Gafter-Gvili A., Leibovici L., Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008, 15:89-102.
125. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
126. Li H.R., Huang J.J., Guo H.Q., Zhang X., Xie Y., Zhu H.L., et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011, 18:877-883.
127. Bruguera M. Prevención de la hepatitis vírica. Enferm Infecc Microbiol Clin 2006, 24:649-656.